Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Anirudh Prahallad, Chong Sun, Sidong Huang, +6

Nature

Gastrointestinal OncologyMedicineFeedback ActivationColorectal CancerPathology +6

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Chong Sun, Liqin Wang, Sidong Huang, +22

Nature

PhotocarcinogenesisMelanomaAdaptive ResistanceRadiation OncologyTumor Biology +1

Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Alberto Bardelli, Simona Corso, Andrea Bertotti, +25

Cancer Discovery

EngineeringPathologyCancer BiologyTumor BiologyCancer Cell Biology +15

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Matthew A. Coelho, Sophie de Carné Trécesson, Sareena Rana, +11

Immunity

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, +15

Journal of Clinical Investigation

Cancer BiologyCellular PhysiologyTumor BiologySignaling PathwayReceptor Tyrosine Kinase +14

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

Chong Sun, Sebastijan Hobor, Andrea Bertotti, +18

Cell Reports

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

Federica Di Nicolantonio, Sabrina Arena, Margherita Gallicchio, +12

Proceedings of the National Academy of Sciences

GeneticsMutated CellsMolecular GeneticsCancer BiologyTumor Biology +20

Combined targeting of G protein‐coupled receptor and <scp>EGF</scp> receptor signaling overcomes resistance to <scp>PI</scp> 3K pathway inhibitors in <scp>PTEN</scp> ‐null triple negative breast cancer

Davide Zecchin, Christopher Moore, Fanourios Michailidis, +4

EMBO Molecular Medicine

The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase

Martina Olivero, Daniela Dettori, Sabrina Arena, +3

Oncotarget

<i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors

Davide Zecchin, Valentina Boscaro, Enzo Médico, +9

Molecular Cancer Therapeutics